Welcome to Drug and Alcohol Treatment
| ||
Drug Treatment Vasculitis Article
This is a selection made from among articles on Drug Treatment Vasculitis. For a permanent link to this article, or to bookmark it for future reading, click here.
Drug Addiction Rehabilitation: Tailoring The Treatment To The Need
from:by Judy Wellsworth
The intensity of drug addiction rehabilitation required by different addicts will vary according to the severity of their addictions. When addicts admit themselves, or are forcibly admitted, to drug addiction rehabilitation facilities, their physical conditions are evaluated so that an appropriate treatment can be determined. There are different drug addiction rehabilitation programs designed to treat the different levels of addiction.Outpatient Treatmenr and DetoxThere are, at the lowest level of drug addiction rehabilitation, intervention and short duration programs, which do not involve any physical treatment. They include court-ordered attendance at classes on the dangers of driving while intoxicated or visits to rehab units for teens caught using drugs or alcohol who has not yet become addicts. They are designed to steer people off the road to addiction before they have traveled to far down it.Detoxification is the second level of drug addiction rehabilitation; just the opposite of short-term intervention, detoxification treats only the physical nature of addiction. The addict is admitted to a facility, remains until he or she is free of the effects of whatever substances caused the admission, and is released. Inpatient TreatmentThe most comprehensive of all the drug addiction rehabilitation programs is inpatient treatment. Inpatient drug addiction rehabilitation requires addicts to take up residence in the facility where they receive their treatment, and the amount of time they stay will depend on how hard they work on confronting their addictions and learning healthier patterns of behavior. Inpatient drug addiction rehabilitation will first include detoxification, with or without the use of sedatives and pain medications; their inclusion will depend both on whether the addict’s system can handle any more chemicals, and whether those running the program believe going “cold turkey” when withdrawing is the best deterrent to future substance abuse.Once the detoxification is over, the addicts will spend their days learning to take responsibility by having jobs assigned to them; going to individual and group counseling sessions, and getting at the emotional causes underlying their dependencies. The process can last for a month of for a year, depending on the severity of the addiction. Inpatient drug addiction rehabilitation is a last resort.Therapeutic techniques in inpatient facilities may include journaling so that the addicts can learn both self-observation skills and how to recognize the situations in which their cravings for drugs are triggered.Choosing the appropriate drug addiction rehabilitation is a matter of balancing the severity of the addiction with the addict’s desire for recovery.
You can also find more information at Drug Addiction Treatment and Drug Addiction Centers. Drugtreatmentinfo.org is a comprehensive resource to known more about drug addiction.
Drug Treatment Vasculitis Specific links
Drug Treatment Vasculitis News
ChemoCentryx Presents Data on CCX168, an Orally Administered Small Molecule ... - MarketWatch (press release)
ChemoCentryx Presents Data on CCX168, an Orally Administered Small Molecule ... MarketWatch (press release) CCX168 is currently in a multinational, randomized, double-blind, placebo-controlled Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis, an inflammation of small blood vessels in the ... ChemoCentryx Announces Transfer of Existing Shares Between Current Stockholders |
ChemoCentryx Announces Transfer of Existing Shares Between Current Stockholders - MarketWatch (press release)
ChemoCentryx Announces Transfer of Existing Shares Between Current Stockholders MarketWatch (press release) ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, ... |
Five-Year Mortality for Rheumatoid Vasculitis Around 60 Percent - About - News & Issues
Five-Year Mortality for Rheumatoid Vasculitis Around 60 Percent About - News & Issues Two patients had been treated with biologic drugs. All but one patient had been treated with intravenous cyclophosphamide. While newer treatments seem to have had an effect on incidence of systemic rheumatoid vasculitis, the treatments have not ... |
What is Wegener's granulomatosis, and how is it treated? - Newsolio
 Newsolio | What is Wegener's granulomatosis, and how is it treated? Newsolio Wegener's granulomatosis is considered one of the many vasculitis syndromes. Vasculitis means an inflammation of blood vessels, and the word granulomatosis refers to a particular type of inflammatory reaction in the affected tissue. |
Prolia Linked to Serious Skin Side Effects - MedPage Today
Prolia Linked to Serious Skin Side Effects MedPage Today Only a handful of reports involved the Xgeva formulation that's used to treat cancer-induced bone disease (120 mg every 4 weeks). "We have no explanation for finding serious adverse events with the 60-mg dose of the drug but not with the 120-mg dose," ... |
ChemoCentryx Announces First Quarter 2012 Financial Results - MarketWatch (press release)
ChemoCentryx Announces First Quarter 2012 Financial Results MarketWatch (press release) "Our enterprise is dedicated to advancing its clinical development pipeline this year, including our wholly owned CCR2 inhibitor, CCX140-B, which is in clinical trials to treat diabetic nephropathy, a devastating kidney disease associated with diabetes ... |
GSK, HGS Saddle Up for Acquisition Battle Valuing HGS at $2.6B - Genetic Engineering News
GSK, HGS Saddle Up for Acquisition Battle Valuing HGS at $2.6B Genetic Engineering News The drug gained the accolade of first new lupus therapy in 50 years when it received FDA approval in March 2011 for systemic lupus. EC and Health Canada followed suit. Despite being hailed as a breakthrough, market adoption has been slow, though. |
Understanding Urinalysis Clues for the Obstetrician-Gynecologist - Medscape
Understanding Urinalysis Clues for the Obstetrician-Gynecologist Medscape American Medical Association Diagnostic and Treatment Guidelines on Domestic Violence. Arch. Fam. Med. 1(1), 39–47 (1992). Stashower M, Rennie T, Turiansky G, Gilliland W. Ovarian cancer presenting as leukocytoclastic vasculitis. J. Am. Acad. Dermatol. |
Alexion Pharmaceuticals Management Presents at Deutsche Bank Securities, Inc ... - Seeking Alpha
Alexion Pharmaceuticals Management Presents at Deutsche Bank Securities, Inc ... Seeking Alpha It's in Phase 2. We acquired this drug recently from Enobia. cPMP replacement therapy for molybdenum cofactor deficiency Type A, this is in preclinical phase. This was acquired last year from Orphatec. TT30 comes into Alexion from Taligen. |